Fresenius SE Cash on Hand 2016-2024 | FSNUY
Fresenius SE cash on hand from 2016 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Fresenius SE cash on hand for the quarter ending September 30, 2024 was $3.221B, a 170.24% increase year-over-year.
- Fresenius SE cash on hand for 2023 was $2.773B, a 4.26% decline from 2022.
- Fresenius SE cash on hand for 2022 was $2.896B, a 11.43% decline from 2021.
- Fresenius SE cash on hand for 2021 was $3.27B, a 55.84% increase from 2020.
Fresenius SE Annual Cash on Hand
(Millions of US $) |
| 2023 |
$2,773 |
| 2022 |
$2,896 |
| 2021 |
$3,270 |
| 2020 |
$2,098 |
| 2019 |
$1,852 |
| 2018 |
$3,199 |
| 2017 |
$1,849 |
| 2016 |
$1,747 |
| 2015 |
$1,159 |
Fresenius SE Quarterly Cash on Hand
(Millions of US $) |
| 2024-09-30 |
$3,221 |
| 2024-06-30 |
$2,862 |
| 2024-03-31 |
$1,106 |
| 2023-12-31 |
$2,773 |
| 2023-09-30 |
$1,192 |
| 2023-06-30 |
$2,694 |
| 2023-03-31 |
$2,491 |
| 2022-12-31 |
$2,896 |
| 2022-09-30 |
$2,143 |
| 2022-06-30 |
$2,266 |
| 2022-03-31 |
$2,331 |
| 2021-12-31 |
$3,270 |
| 2021-09-30 |
$2,845 |
| 2021-06-30 |
$2,711 |
| 2021-03-31 |
$2,263 |
| 2020-12-31 |
$2,098 |
| 2020-09-30 |
$3,107 |
| 2020-06-30 |
$3,384 |
| 2020-03-31 |
$2,237 |
| 2019-12-31 |
$1,852 |
| 2019-09-30 |
$1,778 |
| 2019-06-30 |
$1,644 |
| 2019-03-31 |
$1,753 |
| 2018-12-31 |
$3,199 |
| 2018-09-30 |
$2,856 |
| 2018-06-30 |
$2,704 |
| 2018-03-31 |
$1,824 |
| 2017-12-31 |
$1,849 |
| 2017-09-30 |
$1,730 |
| 2017-06-30 |
$1,508 |
| 2017-03-31 |
$1,577 |
| 2016-12-31 |
$1,747 |
| 2016-09-30 |
$1,311 |
| 2016-06-30 |
$1,240 |
| 2016-03-31 |
$973 |
| 2015-12-31 |
$1,159 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$21.703B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
